A new screening tool for FGFR inhibitor treatment?
Mené sur 103 patients atteints d'un cancer de stade avancé surexprimant FGFR, cet essai de phase I analyse les caractéristiques pharmacocinétiques et la dose maximale tolérée du rogaratinib, un inhibiteur de FGFR dispensé par voie orale
Major advances in targeted therapy and immunotherapy has revolutionised the treatment of cancer. With the advent of personalised medicine, a one-size-fits-all approach is no longer appropriate. Our aim to personalise cancer treatment based on the molecular landscape of tumours has led to development of biomarker-driven strategies to improve treatment outcomes.
The Lancet Oncology , commentaire, 2018